Business Context and Reporting Period
This Form 8-K is filed by iBio, Inc. on November 4, 2025. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Stock Market LLC under trading symbol IBIO.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to a notification of regulatory compliance status.
Material Changes
The primary material change reported is the resolution of a prior listing deficiency:
- Previous Status: On July 29, 2025, iBio received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days (June 13, 2025, to July 28, 2025).
- Current Status: On November 4, 2025, the company received notice from Nasdaq confirming it has regained compliance with the rule.
- Outcome: The listing matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies. The document solely confirms the closure of the specific listing compliance issue.
Investor Verification Checklist
- Verify the current trading price of IBIO to ensure it remains above the $1.00 threshold to prevent future non-compliance notices.
- Review the company's most recent 10-Q or 10-K filings for actual financial performance data, as this 8-K contains none.
- Confirm that no other pending regulatory actions exist with Nasdaq or the SEC.